Medscape Oncology (@MedscapeOnc) header
Medscape Oncology (@MedscapeOnc) profile picture

Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.

Joined May 2009
Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)Photo by Medscape Oncology (@MedscapeOnc)
Managing refractory HSV in immunocompromised patients requires moving beyond IV foscarnet. Our expert panel breaks down clinical evidence, toxicity hurdles, and oral options. Watch the expert breakdown here ➡️ mdsc.pe/4A89e1B #InfectiousDisease #CME #MedEd
110
How does mNGS fit into your diagnostic approach? Join experts to review available tests and best-use practices for evaluating suspected infections in immunocompromised patients. 🔗 mdsc.pe/4yt5g3c
105
🔬 How can you optimize care for patients with newly diagnosed multiple myeloma ? Explore clinical evidence for transplant-eligible and ineligible patients, personalized treatment strategies, and the importance of collaborative care. 💡 Strengthen your clinical decision-making—join this educational activity! mdsc.pe/3U0ktts #ASH26
161
🧬 What's new in sickle cell disease (SCD) care? Explore gene therapies, emerging PK activators, and personalized treatment strategies. 🔍 Expand your clinical knowledge—join this educational activity! mdsc.pe/4zpr7Zo #ASH26
198
💊 Optimizing R/R DLBCL treatment requires evidence-based decisions! Explore bispecific antibody trial findings, treatment sequencing, and practical strategies for community-based care. 🎯 Enhance your expertise! mdsc.pe/4ex4Q3I #ASH26
187
🧬 What's new in #HER2Mutated advanced #NSCLC? 🔬 Explore emerging targeted therapies, personalized treatment strategies, and multidisciplinary approaches to identifying eligible patients. 💡 Advance your clinical expertise! mdsc.pe/48ZJUiH
174
Grow your expertise in emerging oral endocrine therapies. This new Medscape activity guides you through the latest evidence, patient selection, sequencing, and team-based strategies in early breast cancer so you can shape care with authority. mdsc.pe/4z5AwF8
198
🧪 Advancing care for systemic mastocytosis starts with the latest evidence happening at #ASH26! Explore clinical trial findings, assess disease control, and enhance interprofessional treatment decisions. 🚀 Stay informed—join this educational activity! mdsc.pe/4yfvJ3h
208
👉 Sharpen your approach to AL amyloidosis! 💬 Differentiate amyloid disorders, interpret treatment data, personalize therapy, and strengthen coordinated workflows to support timely, effective care. mdsc.pe/4x5jqGX #ASH26
2
290
🩸 At #ASH26, explore the latest data on bispecific antibodies for R/R DLBCL, including when transplant or CAR T may not be suitable. Gain practical insights to inform treatment decisions. Register today: mdsc.pe/4yldhag
2
379
💊 Optimizing R/R DLBCL treatment requires evidence-based decisions! Explore bispecific antibody trial findings, treatment sequencing, and practical strategies for community-based care. 🎯 Enhance your expertise! mdsc.pe/4ex4Q3I #ASH26
1
301
Struggling to choose between DNA vs. RNA-based NGS for NTRK fusions? Dr. Ibiayi Dagogo-Jack and Dr. Nabil F. Saba explain why RNA-based assays, and plasma testing when tissue is limited, are critical for detection. Watch the full discussion ➡️ mdsc.pe/4jb6VFn #CME #Oncology #NTRK
231
🧬 Choosing the right TKI in CML starts with the right data. Explore first-line selection, navigate resistance & translate mutational analysis into therapeutic decisions with coordinated team-based care. 🎯 Sharpen your CML strategy—register today! mdsc.pe/4zRXX6p #ASH26
210
🧪 Advancing care for systemic mastocytosis starts with the latest evidence happening at #ASH26! Explore clinical trial findings, assess disease control, and enhance interprofessional treatment decisions. 🚀 Stay informed—join this educational activity! mdsc.pe/4yfvJ3h
210
Proud to sponsor Caregiver Central at @BloodCancerUtd New Jersey's Light The Night in Mercer County. 🏮 Better care starts when clinician education reflects patient and caregiver realities. pmlive.com/pmhub/medscape_ed… #LightTheNight #BloodCancerUnited
311
🧠 What does treatment success really look like in hemophilia? Move beyond bleeding rates, compare meaningful differences across therapies, and personalize care around the factors that matter to each patient. 🪄 Bring a fresh perspective to hemophilia care! mdsc.pe/4irU5mb #ASH26
191
Advance your practice with new education on oral SERD eligibility in EBC. Gain expert insight into landmark trials, learn exactly who qualifies for novel therapies, and elevate the care you deliver and the outcomes you can achieve for the patients you treat every day. .mdsc.pe/4z5AwF8
241
📌 #ASH26 is BACK! 🚀 Ready to bring bispecific antibodies into R/R MM care? Review key🔑 trial data, navigate barriers to implementation, and explore strategies to manage AEs while expanding access. 🧩 Build individualized care plans with confidence. Save your spot! mdsc.pe/3Sy3Apg
253
🔮 Is your patient’s SM truly under control? Dive into emerging evidence across the spectrum of systemic mastocytosis and 🧬 sharpen your ability to recognize when advanced treatment may be needed. 📣 Bring the latest evidence into practice! mdsc.pe/4yhO28u #ASH26
216
Episodic therapy, not suppression, is often the real risk factor for refractory HSV. Hear Dr. Anna Wald and Dr. Princy Kumar review why clinical resistance happens and how care is evolving. Catch the replay ➡️ mdsc.pe/4A89e1B #InfectiousDisease #CME #MedEd
296